Inhibikase Posts Wider Loss in Q2
Inhibikase Therapeutics (NASDAQ:IKT) released its earnings for the quarter ended June 30, 2025 on August 14, 2025. The company reported a GAAP net loss per share of $0.11, wider than the analyst expectation of a GAAP loss of $0.08 per share. There was no revenue as the company remains pre-commercialization. Expenses rose sharply due to pipeline investments and acquisition effects, leading to a GAAP net loss of $9.9 million, up from $5.0 million in Q2 2024. However, it ended the period with $87.7 million in cash and securities but highlighted ongoing pressures from rising operating costs as the company advances its late-stage clinical trial program.
Source: Analyst estimates for the quarter provided by FactSet.
Inhibikase Therapeutics pursues new therapies for serious diseases like Parkinson's Disease and pulmonary arterial hypertension (PAH).
Source Fool.com
